Astrazeneca (AZN) Cash & Equivalents (2009 - 2026)

Astrazeneca's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $4.9 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 30.58% year-over-year to $4.9 billion; the TTM figure through Jun 2026 stood at $4.9 billion (down 30.58% YoY), while the FY2025 annual figure was $5.7 billion, up 4.06% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $4.9 billion, down from $7.6 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $8.1 billion in Q3 2025, with the low at $4.5 billion in Q3 2022.
• The 5-year median for Cash & Equivalents is $5.7 billion (2022), against an average of $6.0 billion.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 69.06% in 2022, then soared 69.75% in 2025.
• Astrazeneca's Cash & Equivalents stood at $6.2 billion in 2022, then decreased by 5.29% to $5.8 billion in 2023, then retreated by 6.03% to $5.5 billion in 2024, then rose by 4.06% to $5.7 billion in 2025, then retreated by 14.2% to $4.9 billion in 2026.
• Business Quant data shows AZN's Cash & Equivalents at $4.9 billion in Q2 2026, $7.6 billion in Q1 2026, and $5.7 billion in Q4 2025.